Last month, C4 Therapeutics dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, combined with ...
Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today publication online in Scientific Reports -- Nature, of collaborative studies with Duke ...
Anemia often goes hand-in-hand with multiple myeloma. Sometimes, the cancer causes the anemia. And sometimes, the cancer treatment does. But it's possible to resolve it and feel better. (Photo Credit: ...
Multiple myeloma care shifts to four-drug frontline regimens and MRD testing, boosting deep responses and guiding relapse ...
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been ...
The FDA approved a steroid-sparing Tecvayli and Darzalex Faspro combo for relapsed myeloma, offering an 83% reduction in ...
While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...
This Multiple Myeloma Awareness Month, Dr Brid Seoighe, medical director at Johnson & Johnson Innovative Medicine Ireland, ...
Survival in myeloma is clearly being prolonged,” says Mikhael. “Whereas historically, we saw a greater impact in younger ...
The debate around the word “cure.” ...
Multiple myeloma is a blood cancer affecting plasma cells, causing abnormal antibody production and bone damage. Diagnosis involves blood tests, bone marrow biopsy, imaging, and genetic analysis to ...
How Does Multiple Myeloma Impact the Kidneys? Multiple myeloma is a cancer of plasma cells, a type of immune cell found in bone marrow. Healthy plasma cells make proteins called antibodies to fight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results